PCa Commentary | Volume 153 – May 2021
This Commentary provides an overview of PSMA-targeted radioligand therapy with Lutetium-177 or Actinium-225 and positive impact on progression-free survival.
Read MoreSelect Page
Posted by Edward Weber, MD | May 2021
This Commentary provides an overview of PSMA-targeted radioligand therapy with Lutetium-177 or Actinium-225 and positive impact on progression-free survival.
Read MorePosted by Edward Weber, MD | Apr 2021
This Commentary provides a primer on using genomic classifiers and genomic sequencing to guide management decisions for prostate cancer.
Read MorePosted by Greg Donohue | Mar 2021
This Commentary will addresses the guidance from four clinical trials regarding patient selection and imaging choices to best select patients most likely to benefit from MDT.
Read MorePosted by Edward Weber, MD | Dec 2020
This Commentary discusses how olaparib and rucaparib offer a needed additional treatment option for men with mCRPC.
Read MorePosted by Greg Donohue | Nov 2020
This Commentary discusses how olaparib and rucaparib offer a needed additional treatment option for men with mCRPC.
Read More